Drug Landscape ›
Activated protein C ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 11
Most-reported reactions
Septic Shock — 2 reports (18.18%) Ascites — 1 report (9.09%) Atelectasis — 1 report (9.09%) Blood Creatine Increased — 1 report (9.09%) Blood Lactic Acid Increased — 1 report (9.09%) Blood Ph Increased — 1 report (9.09%) Blood Sodium Decreased — 1 report (9.09%) Blood Urea Increased — 1 report (9.09%) Death — 1 report (9.09%) Febrile Neutropenia — 1 report (9.09%)
Source database →
Activated protein C in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Activated protein C approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for Activated protein C in United States?
Helsinki University Central Hospital is the originator. The local marketing authorisation holder may differ — check the official source linked above.